Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival
-
Published:2023-04-01
Issue:10
Volume:41
Page:1849-1863
-
ISSN:0732-183X
-
Container-title:Journal of Clinical Oncology
-
language:en
-
Short-container-title:JCO
Author:
Lopes Cardozo Josephine M.N.12ORCID, Andrulis Irene L.34ORCID, Bojesen Stig E.567ORCID, Dörk Thilo8ORCID, Eccles Diana M.9ORCID, Fasching Peter A.10ORCID, Hooning Maartje J.11ORCID, Keeman Renske12ORCID, Nevanlinna Heli13, Rutgers Emiel J.T.1ORCID, Easton Douglas F.1415ORCID, Hall Per1617ORCID, Pharoah Paul D.P.1415, van 't Veer Laura J.18ORCID, Schmidt Marjanka K.121920ORCID, Ahearn Thomas U., Anton-Culver Hoda, Arndt Volker, Auer Paul L., Augustinsson Annelie, Beane Freeman Laura E., Becher Heiko, Beckmann Matthias W., Behrens Sabine, Benitez Javier, Bermisheva Marina, Blomqvist Carl, Bolla Manjeet K., Bonanni Bernardo, Boyle Terry, Brenner Hermann, Brucker Sara Y., Brüning Thomas, Burwinkel Barbara, Buys Saundra S., Camp Nicola J., Canzian Federico, Cardoso Fatima, Castelao Jose E., Cessna Melissa H., Chan Tsun L., Chang-Claude Jenny, Chenevix-Trench Georgia, Choi Ji-Yeob, Colonna Sarah V., Copson Ellen, Couch Fergus J., Cox Angela, Cross Simon S., Czene Kamila, Daly Mary B., Dennis Joe, Devilee Peter, Drukker Caroline A., Dunning Alison M., Dwek Miriam, Eliassen A. Heather, Engel Christoph, Evans D. Gareth, Figueroa Jonine D., Fletcher Olivia, Flyger Henrik, Gago-Dominguez Manuela, García-Closas Montserrat, García-Sáenz José A., Genkinger Jeanine, Giles Graham G., González-Neira Anna, Guénel Pascal, Gündert Melanie, Hahnen Eric, Haiman Christopher A., Håkansson Niclas, Hamann Ute, Hartman Mikael, Heemskerk-Gerritsen Bernadette A.M., Hein Alexander, Ho Weang-Kee, Hoppe Reiner, Hopper John L., Houlston Richard S., Howell Anthony, Hunter David J., Ito Hidemi, Jakubowska Anna, Jernström Helena, John Esther M., Johnson Nichola, Jones Michael E., Joseph Vijai, Kaaks Rudolf, Kang Daehee, Kim Sung-Won, Kitahara Cari M., Koppert Linetta B., Kosma Veli-Matti, Kraft Peter, Kristensen Vessela N., Kubelka-Sabit Katerina, Koutros Stella, Kurian Allison W., Kwong Ava, Lacey James V., Lambrechts Diether, Le Marchand Loic, Li Jingmei, Lubiński Jan, Lush Michael, Mannermaa Arto, Manoochehri Mehdi, Margolin Sara, Matsuo Keitaro, Mavroudis Dimitrios, Michailidou Kyriaki, Milne Roger L., Mohd Taib Nur Aishah, Mulligan Anna Marie, Neven Patrick, Newman William G., Obi Nadia, Offit Kenneth, Olshan Andrew F., Park Sue K., Park-Simon Tjoung-Won, Patel Alpa V., Plaseska-Karanfilska Dijana, Poncet Coralie, Prentice Ross L., Presneau Nadege, Prevos Renate, Pylkäs Katri, Radice Paolo, Rennert Gad, Rennert Hedy S., Romero Atocha, Saloustros Emmanouil, Sawyer Elinor J., Schmutzler Rita K., Schwentner Lukas, Scott Christopher, Shah Mitul, Shen Chen-Yang, Shu Xiao-Ou, Sim Xueling, Southey Melissa C., Stone Jennifer, Stram Daniel O., Tamimi Rulla M., Teo Soo Hwang, Teras Lauren R., Terry Mary Beth, Tomczyk Katarzyna, Tomlinson Ian, Troester Melissa A., Truong Thérèse, Vachon Celine M., van Ongeval Chantal, Wang Qin, Wappenschmidt Barbara, Wendt Camilla, Winqvist Robert, Wolk Alicja, Wu Anna H., Yadav Siddhartha, Yip Cheng Har, Zheng Wei, Ziogas Argyrios,
Affiliation:
1. Department of Surgery, The Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands 2. European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium 3. Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada 4. Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada 5. Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark 6. Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark 7. Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark 8. Gynaecology Research Unit, Hannover Medical School, Hannover, Germany 9. Faculty of Medicine, University of Southampton, Southampton, United Kingdom 10. Department of Gynecology and Obstetricss, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany 11. Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands 12. Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands 13. Department of Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland 14. Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom 15. Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom 16. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden 17. Department of Oncology, Södersjukhuset, Stockholm, Sweden 18. UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 19. Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands 20. Department of Clinical Genetics, Leiden University Medical Center, Leiden, the Netherlands
Abstract
PURPOSE A polygenic risk score (PRS) consisting of 313 common genetic variants (PRS313) is associated with risk of breast cancer and contralateral breast cancer. This study aimed to evaluate the association of the PRS313 with clinicopathologic characteristics of, and survival following, breast cancer. METHODS Women with invasive breast cancer were included, 98,397 of European ancestry and 12,920 of Asian ancestry, from the Breast Cancer Association Consortium (BCAC), and 683 women from the European MINDACT trial. Associations between PRS313 and clinicopathologic characteristics, including the 70-gene signature for MINDACT, were evaluated using logistic regression analyses. Associations of PRS313 (continuous, per standard deviation) with overall survival (OS) and breast cancer–specific survival (BCSS) were evaluated with Cox regression, adjusted for clinicopathologic characteristics and treatment. RESULTS The PRS313 was associated with more favorable tumor characteristics. In BCAC, increasing PRS313 was associated with lower grade, hormone receptor–positive status, and smaller tumor size. In MINDACT, PRS313 was associated with a low risk 70-gene signature. In European women from BCAC, higher PRS313 was associated with better OS and BCSS: hazard ratio (HR) 0.96 (95% CI, 0.94 to 0.97) and 0.96 (95% CI, 0.94 to 0.98), but the association disappeared after adjustment for clinicopathologic characteristics (and treatment): OS HR, 1.01 (95% CI, 0.98 to 1.05) and BCSS HR, 1.02 (95% CI, 0.98 to 1.07). The results in MINDACT and Asian women from BCAC were consistent. CONCLUSION An increased PRS313 is associated with favorable tumor characteristics, but is not independently associated with prognosis. Thus, PRS313 has no role in the clinical management of primary breast cancer at the time of diagnosis. Nevertheless, breast cancer mortality rates will be higher for women with higher PRS313 as increasing PRS313 is associated with an increased risk of disease. This information is crucial for modeling effective stratified screening programs.
Publisher
American Society of Clinical Oncology (ASCO)
Subject
Cancer Research,Oncology
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|